Mesalamine in the treatment of ulcerative colitis: Novel therapeutic options

Gastroenterology and Hepatology

Volumn 5, Issue 1, 2009, Pages 65-73

  Lichtenstein, Gary R ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

5 ASA; Drug delivery; Mesalamine; Mesalamine granules; Sulfasalazine; Ulcerative colitis

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; APRISO; BALSALAZIDE; EUDRAGIT; MESALAZINE; OLSALAZINE; POLYMER; SALAZOSULFAPYRIDINE; SULFAPYRIDINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AGRANULOCYTOSIS; CANCER RISK; COLORECTAL CANCER; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY; DRUG ABSORPTION; DRUG CAPSULE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG GRANULE; DRUG MECHANISM; DRUG METABOLISM; DRUG PELLET; DRUG RELEASE; DRUG SAFETY; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEMOLYSIS; HUMAN; LIVER INJURY; LUNG FIBROSIS; NAUSEA; REMISSION; REVIEW; TABLET; ULCERATIVE COLITIS; VOMITING;

EID: 61449244695     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Carter MJ, Lobo AJ, Travis S. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(suppl V):v1-v16.
2. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-1385.
3. Sandborn WJ. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations? J Clin Gastroenterol. 2008;42:338-344.
4. Lichtenstein GR, Kamm MA. Review article: 5-aminosalicylate formulations for the treatment of ulcetative colitis-methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa. Aliment Pharmacol Ther. 2008;28:663-673.
5. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 2000;95:3452-3457.
6. MacDermott RP. Progress in understanding the mechanisms of action of 5-aminosalicylic acid. Am J Gastroenterol 2000;95:3343-3345.
7. Svartz N. Sulfasalazine: II. Some notes on the discovery and development of salazopyrin. Am J Gastroenterol. 1988;83:497-503.
8. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977;2:892-895.
9. Klotz U, Maier K, Fischer C, Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med. 1980;303:1499-1502.
10. Allgayer H. Sulfasalazine and 5-ASA compounds. Gastroenterol Clin North Am. 1992;21:643-658.
11. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003;17:29-42.
12. Fernandez-Becker NQ, Moss AC. Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes. Drugs. 2008;68:1089-1103.
13. Safdi AV, Cohen RD. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates. Aliment Pharmacol Ther. 2007;26:1179-1186.
14. Lichtenstein GR, Rubin DT, Sabesin SM, Velayos FS, Vitat P. Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis. Rev Gastroenterol Disord. 2008;8:21-30; quiz 31-32.
15. Nugent SG, Kumar D, Ramptom DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001;48:571-577.
16. Asacol [package insert]. Cincinnati, OH: Procter & Gamble Pharmaceuticals; 2007.
17. Christensen LA, Fallingborg J, Abildgaard K, Jacobsen BA, Sanchez G, et al. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther. 1990;4:523-533.
18. Lialda (mesalamine) [package insett]. Wayne, PA: Shire US Inc; 2007.
19. Fallingborg J, Christensen LA, Jacobsen BA, Rasmussen SN. Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig Dis Sci. 1993;38:1989-1993.
20. Sasaki Y, Hada R, Nakajima H, Fukuda S, Munakata A. Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: colonic luminal pH in normal subjects and patients with Crohn's disease. Am J Gastroenterol. 1997;92:114-118.
21. Pentasa [package insert]. Wayne, PA: Shire US, Inc.; 2007.
22. Azulfidine EN-Tabs [package insert]. New York, NY: Pfizer, Inc.; 2006.
23. Dipentum [package insert]. Kalamazoo, MI: Pharmacia & Upjohn Company; 2001.
24. Colazal [package insert]. Morrisville, NC: Salix Pharmaceuticals, Inc.; 2007.
25. Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002;97:1398-1407.
26. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987;317:1625-1629.
27. Sninsky CA, Cort DH, Shanahan F, Powers BJ, Sessions JT, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: a multicenter study. Ann Intern Med. 1991;115:350-355.
28. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100:2478-2485.
29. Hanauer SB, Schwartz J, Robinson M, Roufail W, Arora S, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol. 1993;88:1188-1197.
30. Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5:95-102.
31. Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007;132:66-75.
32. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):CD000544.
33. Hawthorne AB, Rubin G, Ghosh S. Review article: medication non-adhetence in ulcerative colitis-strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther. 2008;27:1157-1166.
34. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:577-585.
35. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39-43.
36. Tindall WN, Boltri JM, Wilhelm SM. Mild-to-moderate ulcetative colitis: your role in patient compliance and health care costs. J Manag Care Pharm. 2007;13(7 suppl S-A):S2-12.
37. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:191-198.
38. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004;19:179-189.
39. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000;14:145-153.
40. Brentnall TA. Molecular underpinnings of cancer in ulcerative colitis. Curr Opin Gastroenterol. 2003;19:64-68.
41. Ransohoff DF. Colon cancer in ulcerative colitis. Gastroenterology. 1988;94:1089-1091.
42. van Staa TP, Card T, Logan RF, Leufkens HGM. 5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573-1578.
43. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345-1353.
44. Brunner M, Assandri R, Kletter K, Tschurlovits M, Corrado ME, et al. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther. 2003;17:395-402.
45. Brunner M, Greinwald R, Kletter K, Kvaternik H, Corrado ME, et al. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs tablets in male healthy volunteers. Aliment Pharmacol Ther. 2003;17:1163-1169.
46. Press AG, Hauptmann IA, Hauptmann L, Fuchs B, Fuchs M, et al. Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 1998;12:673-678.
47. Kruis W, Bar-Meir S, Feher J, Mickisch O, Mlitz H, et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol. 2003;1:36-43.
48. Kruis W, Kiudelis G, Racz I, Gorelov IA, Pokrotnieks J, et al. Once-daily versus three-times-daily mesalazine granules in active ulcerative colitis: A double-blind, double-dummy, randomised non-inferiority trial. Gut. 2008 Oct 2. [Epub ahead of print].
49. Kruis W. Once daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology. 2008;134:A489. Abstract.
50. Marakhouski Y, Fixa B, Holoman J, Hulek P, Lukas M, et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Aliment Pharmacol Ther. 2005;21:133-140.
51. Russell CL, Conn VS, Jantarakupt P. Older adult medication compliance: integrated review of randomized controlled trials. Am J Health Behav. 2006;30:636-650.
52. Safdi AV, Pieniaszek H, Grigston A, Forbes WP. Minimal effect of a high-fat meal on the pharmacokinetics of once-daily granulated mesalamine. Am J Gastroenterol. 2008;103:1127.
53. Safdi AV, Pieniaszek H, Grigston A, Forbes WP. Multiple-dose pharmacokinetics of granulated mesalamine, a unique formulation providing delayed and extended release of 5-ASA. Am J Gastroenterol. 2008;13:439-440. Abstract 1126.
54. Gordon G, Pruitt RE, Ringold M, Sedghi S, Merchant K, et al. Once-daily 1.5-g granulated mesalamine is effective and safe in maintenance of remission in mild-to-moderate UC. Am J Gastroenterol. 2008;103:1128.
55. Zakko S, Murthy U, Pruitt RE, Merchant K, Shaw A, et al. Safety profile of once-daily 1.5-g granulated mesalamine as maintenance therapy for mild-to-moderate ulcerative colitis: results from 2 phase III trials. Am J Gastroenterol. 2008;103:1119.
56. Lichtenstein GR. Once-daily 1.5-g granulated mesalamine effectively maintains remission in patients with ulcerative colitis who switch from different 5-ASA formulations. Am J Gastroenterol. 2008;103(S1):S429-430. Abstract.